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Edited by Hans-Dieter KlenkAbstract Hepatitis B virus core protein self-assembles into ico-
sahedral, highly immunogenic capsid-like particles (CLPs) that
can serve as molecular platforms for heterologous proteins.
Insertion into the centrally located c/e1 epitope leads to surface
display, fusion to the C terminus to internal disposition of the
foreign domains. However, symmetry-deﬁned space restrictions
on the surface and particularly inside the CLPs limit the size
of usable heterologous fusion partners. Further, CLPs carrying
diﬀering foreign domains are desirable for applications such as
multivalent vaccines, and for structure probing by distance sensi-
tive interactions like ﬂuorescence resonance energy transfer
(FRET). Here, we report an in vitro co-assembly system for such
mosaic-CLPs allowing successful CLP formation with a per se
assembly-deﬁcient fusion protein, and of CLPs from two diﬀer-
ent ﬂuoroprotein-carrying fusions that exert FRET in an assem-
bly-status dependent way.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The 183 amino acid core protein forms the protein shell of
the icosahedral hepatitis B virus (HBV) nucleocapsid (core
particle). Heterologously expressed core protein self-assembles
into morphologically similar capsid-like particles (CLPs). The
ﬁrst about 140 amino acids form the assembly domain, i.e.,
they are suﬃcient for assembly [1,2]; the basic C terminus, in
CLPs mostly located in the particle lumen [3,4], acts as a nu-
cleic acid binding domain [5,6]. Due to its exceptional immu-
nogenicity the core particle, serologically deﬁned as hepatitisAbbreviations: CLP, capsid-like particles; eGFP, enhanced green ﬂu-
orescent protein; FP, ﬂuorescent protein; FRET, ﬂuorescence reso-
nance energy transfer; HBV, hepatitis B virus; mCFP, monomeric cyan
FP; mYFP, monomeric yellow FP; NTA, nitrilotriacetic acid; SDS–
PAGE, sodium dodecylsulphate polyacrylamide gel electrophoresis
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doi:10.1016/j.febslet.2005.08.044B core antigen (HBcAg), is of major interest as a particulate
vaccine carrier for heterologous sequences [7,8]. The predomi-
nant particle form (triangulation number of T = 4) is com-
posed of 120 and a minor form (T = 3) of 90 core protein
dimers [3,9–11]. The most surface-exposed part is a short loop
around amino acid 80 [12], overlapping with the immunodom-
inant c/e1 B cell epitope [13], that connects two long helices
forming the core proteins dimer interface [14,15]. As exempli-
ﬁed by the green ﬂuorescent protein (GFP), even whole protein
domains of at least 238 amino acids can be inserted into this
loop without compromising particle formation [16]. However,
speciﬁc properties of the inserted protein, such as an unfavor-
able molecular shape [17] or the propensity to homo-oligomer-
ize [18], can severely restrain particle assembly. A universal
restriction is the limited space, deﬁned by the particle symme-
try, on the surface and in particular inside the CLP. CLPs with
internally disposed heterologous domains can be obtained by
their fusion to the C terminus of the assembly domain
[19,20]. According to X-ray data of recombinant HBcAg CLPs
ending with amino acid 149 [15] the available inner volume in a
T = 4 CLP is about 9000 nm3, leaving roughly 38 nm3 for each
of the 240 added foreign domains. Indeed, a core fusion pro-
tein with the 17 kDa Staphylococcus aureus nuclease, with an
approximate volume of 36 nm3, fused to aa 155 formed rather
unstable particles [19]. Hence larger heterologous proteins are
expected to prevent assembly (Fig. 1A).
Both surface and internal crowding should be reduced if,
in one particle, some of the fusion protein subunits are re-
placed by sterically less demanding subunits, e.g., non-fused
wild-type protein. Thus far, this mosaic-CLP concept has
been addressed by co-expression of the two diﬀerent protein
subunits, either from two compatible plasmids [19] or by
limited translational read-through [21]. However, these
in vivo approaches oﬀer only limited controllability of the
CLP composition, and little ﬂexibility regarding the nature
and number of the assembly partners. Here, we present an
alternative in vitro co-assembly approach largely overcoming
these limitations. We demonstrate its principal feasibility by
co-assembly of wild-type core protein subunits with an
assembly-competent and an assembly-deﬁcient core-GFP fu-
sion (enhanced green ﬂuorescent protein, eGFP inserted into
c/e1, and fused to aa 148, respectively), and by mosaic-CLP
formation from two core fusions with diﬀerent GFP deriva-
tives that are suitable for ﬂuorescence resonance energy
transfer (FRET).blished by Elsevier B.V. All rights reserved.
Fig. 1. Concept of mosaic HBV CLPs, and core proteins used. (A) Structural aspects. HBV core protein (shown as L-shaped object) forms dimers
that assemble into icosahedral CLPs. The dimer interface is formed by two antiparallel helices per monomer, connected by a short loop overlapping
with the c/e1 epitope around aa 80; the four-helix bundles protrude as spikes from the CLP surface. Foreign proteins as large as GFP (barrel
structures) can be inserted into the loop without compromising assembly; fusion to the C terminus of the core proteins assembly domain leads
instead to an internal disposition (transparent barrel structures), with increased steric crowding. This is relieved if some of the fusion protein subunits
are replaced by non-fused core protein subunits (darker shading), i.e., by mosaic-CLP formation. (B) Schematic representation of the core protein
derivatives used. All proteins contained C terminal His6 tags. HBc1-149_H6 is the wild-type core protein without the basic C terminus; HBc1-149c/
e1G/mC/mYFP_H6 denotes three related fusion proteins, containing between core protein aa 78 and 80 either eGFP, mCFP, or mYFP; in HBc1-
148_ctGFP_H6, eGFP is fused to aa 148 of the core protein. (C) Outline of the in vitro co-assembly procedure. In step 1, a mixture of the assembly
partner proteins is immobilized via their His-tags to a Ni2+-matrix in the presence of urea; in step 2, conditions are shifted, on column, towards
promoting assembly by decreasing the urea and increasing the salt concentration; in step 3, the proteins are eluted from the column by increasing
imidazole concentration. During this process, co-assembly into mosaic-CLPs can occur.
5212 M. Vogel et al. / FEBS Letters 579 (2005) 5211–52162. Materials and methods
2.1. Plasmid constructs
The T7 promoter containing expression plasmids encoding C termi-
nally His6-tagged proteins HBc1-149_H6 (wild-type core protein from
aa 1 to 149) and HBc1-149c/e1eGFP/mCFP/mYFP_H6 (carrying
either eGFP, or monomeric CFP, or monomeric YFP [22] inserted be-
tween aa 78 and 80) have previously been described [18]. pET28a2-
HBc148-ctGFP_H6 encodes core protein 1–148 with eGFP, plus a
C-terminal His6-tag, fused to amino acid 148 via a linker with the se-
quence A(G3S)3G4T. A schematic representation of the proteins is
shown in Fig. 1B.
2.2. Expression and enrichment of core proteins variants
All proteins were expressed using Escherichia coli BL21ÆDE3æ
Codonplus RIL cells (Stratagene). Cell lysis and core protein enrich-
ment by sucrose gradient centrifugation were performed as previously
described [18]. Protein HBc1-148ctGFP_H6, not forming regular
CLPs, was puriﬁed by immobilized metal ion aﬃnity chromatography
(IMAC) on Ni2+–nitrilotriacetic acid (NTA) agarose (Qiagen) under
native conditions as suggested by the manufacturer. Proteins were ana-
lyzed by sodium dodecylsulphate polyacrylamide gel electrophoresis
(SDS–PAGE) using 15% acrylamide and 0.1% SDS in the Laemmli
buﬀer system. For immunoblotting, HBV core protein speciﬁc mono-
clonal antibodies mc312, mc158 or mc275 [23,24], or a monoclonal
antibody mixture against GFP (Roche) were used. Detection was per-
formed using secondary antibody–peroxidase conjugates and a chemi-
luminescent substrate (ECL+, Amersham). Gradient or IMAC
fractions containing the desired proteins were combined, dialyzed
against TN-300 buﬀer (25 mM Tris/HCl, pH 7.5, 300 mM NaCl) and
concentrated by ultra ﬁltration (Amicon Ultra devices, 30 kDa cut-
oﬀ; Millipore). Protein concentrations were determined using the Brad-
ford assay (Bio-Rad).2.3. In vitro co-assembly
Pre-puriﬁed core protein derivatives, at about 1–2 mg/ml, were ad-
justed to dissociation buﬀer (6 M urea, 10 mM imidazole, 50 mM so-
dium phosphate buﬀer, pH 8.0, and 50 mM NaCl), and incubated at
room temperature for 15 min, followed by another 15 min at 37 C;
all subsequent steps were performed at room temperature. The solu-
tions were mixed at the desired molar ratios, and bound to a Ni2+–
NTA column pre-equilibrated in dissociation buﬀer (usually 1–2 ml
protein solution for a 2 ml gel bed column). The urea concentration
was decreased by washing with 2 ml each of washing buﬀer (20 mM
imidazole, 50 mM sodium phosphate, pH 8.0, and 50 mM NaCl) con-
taining 5, 4, 3, 2, 1 and 0.5 M urea, followed by pure washing buﬀer,
then washing buﬀer containing 300 mM NaCl. Finally, twice the gel
bed volume of elution buﬀer (250 mM imidazole, 50 mM sodium phos-
phate buﬀer, pH 8.0, and 300 mM NaCl) was added and, after a
30 min incubation, the proteins were eluted by gravity ﬂow. To sepa-
rate CLPs from non-assembled forms, dialyzed and concentrated sam-
ples were subjected to sedimentation in 10–60% (wt/vol) sucrose step
gradients. Fluorescent mosaic CLPs were detected by visual inspection
upon irradiation with a UV lamp emitting light of 312 or 365 nm.
2.4. Native agarose gel electrophoresis
Aliquots from individual gradient fractions were subjected to elec-
trophoresis in 1% agarose gels in TAE buﬀer (40 mM Tris–acetate,
0.1 mM EDTA, pH 8.0) containing 0.5 lg/ml of ethidium bromide
as previously described [18], and detected directly via their ﬂuorescence
or immunologically after blotting to PVDF membranes.
2.5. Electron microscopy
Electron micrographs were obtained on a Zeiss EM 902 at 80 kV
with nominal magniﬁcation of 85000–140000-fold. Samples from
appropriate sucrose gradient fractions were stained with 2% methyl-
amine tungstate, pH 7.0, as previously described [18].
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Fluorescence measurements were performed at 20 C using a Per-
kin–Elmer LS 45 spectrometer in quartz cuvettes (5 mm light path,
Suprasil; Hellma). All spectra were corrected for lamp intensity and
detector sensitivity. Proteins were used at concentrations of 0.18–
0.9 lg/ll in 25 mM Tris/HCl, pH 7.5, 150 mM NaCl. Data were
recorded with an integration time of 1000 ms. Emission spectra were
recorded at 410 nm as excitation maximum for monomeric cyan FP
(mCFP) fusion proteins and FRET samples, and at 483 nm for mono-
meric yellow FP (mYFP) fusion proteins. The spectra were normalized
to their maxima.Fig. 2. Mosaic-CLPs from an assembly-competent coreGFP fusion
and wild-type core protein. HBc1-149_c/e1GFP_H6 and HBc1-
149_H6 CLPs were subjected to the procedure outlined in Fig. 1C.
The eluate from the Ni–NTA column was sedimented through a 10–
60% sucrose gradient. (A) SDS–PAGE. Aliquots from gradient
fractions 1–12 were analyzed by SDS–PAGE and Coomassie Blue
staining. M, protein size marker; IN, input before sedimentation. (B)
Native agarose gel electrophoresis. Pure HBc1-149_c/e1GFP_H6 and
HBc1-149_H6 CLPs as isolated from the bacteria, and an aliquot of
gradient fraction 7 from the co-assembly reaction were run on an
agarose gel, blotted, and one sample set was probed with anti-core
antibody mc158 (a-HBc), the other with anti-GFP (a-GFP) antibodies,
then visualized using a chemiluminescent substrate.3. Results
3.1. Experimental design
Due to the highly stable fold of the core protein and its dimer
the inter-dimer contacts in HBcAg CLPs can be dissociated,
without denaturation of the subunits, by partially denaturing
conditions [1,25], for instance, depending on the protein con-
centration and the ionic strength of the solution [25], by 2–
6 M urea. This property can be exploited to expose a C terminal
His-tag fused to aa 149, which is buried inside intact CLPs, and
to immobilize the dimers on a Ni2+–NTA matrix. As outlined
in Fig. 1C, the ﬁrst step of our method consists in this urea-
assisted immobilization of the two proteins at a preselected
ratio on the same Ni2+-matrix. Non-assembling His-tagged fu-
sion proteins may directly be immobilized on the matrix. In the
second step, similar to on-column refolding of denatured pro-
teins (for review, see [26]), the buﬀer composition is gradually
altered towards assembly-promoting conditions via decreasing
the urea and increasing the salt concentration; ﬁnally the pro-
teins are eluted by increasing the imidazol concentration. This
general scheme was applied to the diﬀerent protein mixtures re-
ported below. To detect mosaic-CLP formation, the eluates
were dialyzed against high salt buﬀer, concentrated, and ana-
lyzed by sedimentation in sucrose gradients, by native agarose
gel electrophoresis and Western blotting, and by electron
microscopy (EM).3.2. Mosaic-CLPs from wild-type core protein 1–149 and an
assembly-competent coreGFP fusion
For proof of concept, His-tagged wild-type core protein
HBc1-149_H6 and the assemby-competent coreGFP fusion
HBc1-149_c/e1GFP_H6 [18] were bound, at an approximate
1:1 molar ratio, to Ni2+–NTA beads in the presence of urea;
without urea, essentially no binding occurred, consistent with
the C terminal His-tag being inaccessible in intact CLPs.
Employing the above described reassembly procedure the
two proteins co-eluted from the column at 250 mM imidazole
concentration. Upon sedimentation in 10–60% sucrose gradi-
ents approximately one third of the fusion protein, and two
thirds of the wild-type accumulated in the particle-typical cen-
tral fractions [18]; the remainder stayed in the top fractions
(Fig. 2A), suggesting the wild-type protein assembles some-
what more eﬃciently than the fusion protein. To distinguish
true mosaic-CLPs from a mixture of two separate CLP popu-
lations, an aliquot from gradient fraction 7 was subjected to
native agarose gel electrophoresis, in parallel with pure
HBc1-149_H6 and HBc1-149_c/e1GFP_H6 CLPs. After blot-
ting, the membrane was probed with anti-core and anti-GFP
antibodies (Fig. 2B). The unmodiﬁed CLPs migrated substan-
tially faster than the pure coreGFP CLPs whereas, as expectedfor mosaic-CLPs, the co-assembled particles produced a band
of intermediate mobility which was detected by both antibod-
ies; the HBc1-149_H6 CLPs, by contrast, were recognized only
by the anti-core antibody. These data attested to the successful
formation of mosaic-CLPs.
3.3. Rescue of an assembly-deﬁcient core fusion protein by
in vitro co-assembly with wild-type core protein
As a more stringent test for the potential of the method we
next addressed in vitro co-assembly of the HBc1-149_H6 pro-
tein with a per se assembly-deﬁcient core protein fusion. In this
protein, HBc1-148ctGFP_H6, eGFP was fused to core protein
aa 148 (Fig. 1B). This should lead to a luminal disposition of
the GFP domains but the larger volume of GFP (about
47 nm3) was expected to interfere with particle formation.
The protein was well expressed and showed strong green ﬂuo-
rescence, indicating the GFP part was natively folded. How-
ever, on sucrose gradients it displayed a broad distribution
from the top region to the center (Fig. 3A, top panel). This
suggested the presence of at most a small fraction of regular
CLPs and, congruently, mostly irregularly shaped aggregates
were detected by negative staining EM (Fig. 3C). In addition,
the protein bound well to Ni2+–NTA beads in the absence
of urea, indicating the C terminal His tags were solvent
accessible.
Next the fusion protein was mixed with HBc1-149_H6 at mo-
lar ratios of 5:1, 1:1, and 1:5, then the three samples were sub-
jected to the protocol described above. In all cases, both
proteins co-eluted at 250 mM imidazole. After sucrose gradient
Fig. 3. Mosaic-CLPs from an assembly-deﬁcient coreGFP fusion and wild-type core protein. Proteins HBc1-149ctGFP_H6 and HBc1-149_H6 were
subjected to the procedure outlined in Fig. 1C at the indicated molar ratios, then the reaction products were sedimented through sucrose gradients as
in Fig. 2A. (A) SDS–PAGE. Aliquots from gradient fractions were analyzed by SDS–PAGE and Coomassie Blue staining. The top panel shows the
fusion protein alone; the following panels are derived from co-assembly reactions at the indicated fusion protein to wild-type protein ratios. The
arrows indicate the distribution of the wild-type core protein. (B) Native agarose gel electrophoresis. Aliquots from gradient fractions 5–7 of the co-
assembly reactions were analyzed by agarose gel electrophoresis and immunoblotting as in Fig. 2B. Note the gradual shift of the co-assembly
products towards the position of wild-type CLPs. (C) Electron microscopy. Samples from gradient fraction 6 were analyzed by negative staining EM.
The bar corresponds to 50 nm. Note the gradual increase in the fraction of regular CLPs.
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sion protein in excess, the distribution of the fusion protein was
similar as in the absence of wild-type protein; notably, even the
wild-type protein was shifted towards the top of the gradient
(Fig. 3A, 5:1), suggesting a negative eﬀect on assembly by the
fusion protein. By contrast, at a 1:1 ratio a distinct peak for
both proteins was seen in fractions 5–7; about one half of the
fusion protein remained in the top fractions (Fig. 3A, 1:1). With
excess wild-type protein ﬁnally, both proteins were conﬁned to
fractions 5–7 (Fig. 3A, 1:5). To conﬁrm the presence of mosaic-
CLPs, gradient fractions 5–7 from the three assembly reactions
were analyzed by native agarose gel electrophoresis and subse-
quent immuno-blotting with anti-core and anti-GFP antibodes;
pure HBc1-149_H6 CLPs and HBc1-149ctGFP_H6 proteins
served as references. The fusion protein itself, recognized by
both anti-core and anti-GFP antibodies, migrated as a rela-
tively broad band with distinctly lower mobility than pure
HBc1-149_H6 CLPs (Fig. 3B). With increasing proportion of
wild-type protein in the assembly reaction, the mobility in-
creased to nearly that of pure wild-type CLPs, as expected for
internally disposed heterologous domains. Consistently, nega-
tive staining EM conﬁrmed a decreased proportion of irregular
particles and a concomitant increase of regular CLPs with
approximately wild-type CLP diameters of, on average, less
than 30 nm (Fig. 3C). Hence in vitro co-assembly with the
wild-type core protein rescued an assembly-deﬁcient fusion
protein into regular CLPs.3.4. Formation of mosaic CLPs from two diﬀerent fusion
proteins and proof of their mosaic nature by FRET
A further application for co-assembly would be the genera-
tion of mosaic-CLPs from two or more diﬀerent fusion pro-
teins. An attractive model combination are two diﬀerent
GFP derivatives whose spectral properties allow for FRET.
Because FRET depends on spatial proximity between donor
and acceptor, mosaic-CLPs, but not a mixture of two separate
CLP populations, should give rise to FRET. The cyan (CFP)
and yellow (YFP) ﬂuorescent proteins are an established
FRET donor–acceptor pair [27], and their monomeric vari-
ants, mCFP and mYFP [22], can individually be inserted into
the core c/e1 epitope yielding ﬂuorescent CLPs [18]. The dis-
tance between two neighboring spikes on wild-type CLPs is
about 5 nm [15], close to the Foerster radius (distance at which
energy transfer eﬃciency is 50 %) for CFP-YFP and hence ide-
ally suited for FRET. Therefore, HBc1-149-c/e1-mCFP-H6
and HBc1-149-c/e1-mYFP-H6, at an equimolar ratio, were
subjected to the in vitro co-assembly procedure. Both proteins
co-eluted from the Ni2+–NTA column, and about half of both
proteins co-sedimented into the particle-typical gradient frac-
tions. Native agarose gel electrophoresis showed a distinct
band with nearly the same mobility as that of the pure mCFP-
and mYFP-containing CLPs (Fig. 4A). The similar mobilities
and the lack of antibodies speciﬁcally recognizing mCFP but
not mYFP or vice versa prevented a conventional assessment
of mosaic-CLP formation. Instead, the CLPs were analyzed
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spectra of the individual CLPs were very similar to those of
the unfused ﬂuorescent proteins, with emission maxima at
474 nm (plus a sideband around 500 nm) for the mCFP- andFig. 4. Co-assembly of FRET-suited coreGFP fusion variants. Core
protein fusions HBc1-149_c/e1mCFP_H6 and HBc1-149_c/
e1mYFP_H6 were co-assembled as outlined in Fig. 1C, and the
reaction products were separated by sucrose gradient sedimentation
as in Fig. 2A. (A) Native agarose gel electrophoresis. An aliquot from
gradient fraction 7 was analyzed in parallel with pure mCFP- and
mYFP-containing CLPs, and detected via ﬂuorescence. (B) Mosaic-
CLPs but not mixed CLPs exert FRET. The emission spectra of pure
mCFP- and mYFP-containing CLPs (dashed blue and orange lines),
or a 1:1 mixture, or the co-assembly product were recorded by
ﬂuorescence spectroscopy. At 410 nm excitation, the mixture (green
line) displayed a nearly identical spectrum as pure mCFP-CLPs
whereas the co-assembled sample (red line) showed a strong peak at
the 530 mYFP emission maximum, and a reduced emission at the
474 nm mCFP maximum. (C) FRET-monitoring of urea-mediated
CLP dissociation. The co-assembled and the mixed sample were
incubated with urea, and the emission spectra were recorded as in (B).
Compared to the co-assembled sample prior to urea treatment (thin
red line with shaded area underneath), the 530 nm peak was strongly
reduced whereas the 474 nm emission increased (thick black line). The
signal from the mixed CLPs remained essentially unchanged (thick
green line).at 530 nm for the mYFP-containing CLPs (Fig. 4B, dashed
blue and orange lines). When irradiated at 410 nm for speciﬁc
excitation of mCFP with minimal mYFP excitation, the emis-
sion spectrum of a 1:1 mixture of preformed CLPs (green line)
was very similar to that of pure mCFP-containing CLPs. By
contrast, the co-assembled CLPs (red line) yielded a strong
peak at the 530 nm mYFP emission maximum while the mCFP
emission at 474 nm was reduced, exactly as expected for eﬃ-
cient FRET. To prove that dynamic changes in the capsid sta-
tus can be monitored, the co-assembled CLPs were incubated
with 6 M urea. Upon this treatment, the emission spectrum
showed a strong reduction in the 530 nm peak, and a simulta-
neous ﬂuorescence increase at the 474 nm mCFP peak
(Fig. 4C, black line), fully consistent with urea-induced disso-
ciation of the mosaic-CLPs. The spectra of the individual ﬂu-
oroprotein-presenting CLPs and their mixture (Fig. 4C, green
line) remained unaﬀected, conﬁrming the ﬂuorophores them-
selves were stable under these conditions.4. Discussion
The here described in vitro co-assembly method overcomes
several of the limitations of previous in vivo co-expression ap-
proaches for mosaic-CLP generation: the procedure is straight-
forward; using prepuriﬁed components, the input amounts of
each subunit are easily controlled, allowing, to a much larger
extent, the proportion of the individual subunits per particle
to be adjusted; most likely, more than two diﬀerent subunits
could be co-assembled in this way; not the least, the method
allowed for the ﬁrst time to monitor HBV CLP formation,
and disassembly, by the sensitive FRET technique.
Several lines of evidence support the formation of true mo-
saic-CLPs. Co-assembly of HBc1-149_H6 with the assembly-
competent HBc1-149c/e1-eGFP_H6 gave rise to particles
which displayed an intermediate electrophoretic mobility on
native agarose gels. A fusion of eGFP to the C terminus of
the core protein assembly domain formed essentially no sta-
ble CLPs on its own but did so upon co-assembly with
HBc1-149_H6, fully consistent with reduced luminal crowd-
ing. Hence the co-assembly approach with wild-type core
protein enables particle formation for fusions that are too
bulky to assemble into closed shells on their own, and heter-
ologous proteins considerably larger than the 238 aa GFP
should be amenable to presentation on, or packaging into,
HBV CLPs.
The co-assembly data for fusions with mCFP and mYFP
demonstrate the feasibility of generating CLPs containing
two, and probably more, diﬀerent heterologous domains per
particle. In particular, they provide a novel means for spectro-
scopic analyses of HBV capsid assembly and disassembly. Our
data clearly conﬁrm mosaic CLP formation by the unique
FRET signal observed for co-assembled but not mixed CLPs.
Moreover, the intensity of the FRET signal strongly suggests
a mCFP to mYFP distance close to the Foerster radius for this
FRET pair, congruent with a random distribution of the diﬀer-
ently labeled subunits on the particles. Mosaic CLPs containing
these, or other suitable chromophores, should therefore become
valuable tools to quantitatively assessHBVnucleocapsid assem-
bly and disassembly but also to screen for capsid-targeting
antivirals such as the recently described heteroarylpyrimidines
5216 M. Vogel et al. / FEBS Letters 579 (2005) 5211–5216[28]. Finally, using core proteins containing the arginine-rich C
terminal domain the approach may be adapted for the in vitro
encapsidation of selected nucleic acids.
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